Fig. 1From: Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepirideHeatmap depicting log2 transformed levels of metabolites at baseline and after treatment [glimepiride + metformin (G) vs. liraglutide + metformin (L)]. Groups were further divided into subjects with myocardial infarction (MI) or without MI (C, control)Back to article page